Document is current
Any future updates will be listed below
-
Authors
Tseng, Hubert
Dholaria, Bhagirathbhai https://orcid.org/0000-0003-2371-3655
Cranert, Stacey A.
Richter, Maximilian
Marquez, Karl S.
Cho, Benjamin S.
Bacong, Andrew
McArthur, Katherine
Eskew, Jeff D.
McCaigue, Joanne
Haag, Sabrina
Krasny, Aly
Solimine, Brian
Coffey, Michael J.
Loyola, Aimee
Kwong, Jasmine
Shune, Leyla
Kin, Andrew https://orcid.org/0000-0002-3263-2374
Costello, Caitlin L.
Kocoglu, Mehmet H.
Ramakrishnan, Aravind
Namini, Hamid
Martin, Christopher E.
Belani, Rajesh
Coronella, Julia
Shedlock, Devon J. https://orcid.org/0000-0003-1018-7510
- License Information
-
More Information
Article History
Received: 30 September 2024
Accepted: 13 October 2025
First Online: 24 November 2025
Competing interests
: H.T., S.A.C., M.R., K.S.M., B.S.C., A.B., K.M., J.D.E., J.M., S.H., A.Kr., B.S., M.J.C., A.L., J.K., H.N., C.E.M., R.B., J.C., and D.J.S. were employees of Poseida Therapeutics during their contribution to this study. B.D. has received research funding from Janssen Pharmaceuticals, Angiocrine Bioscience, Pfizer, Poseida Therapeutics, MEI Pharma, Orca Bio, Wugen, AlloVir, Adicet Bio, Bristol Myers-Squibb (BMS), Molecular Templates, Atara Biotherapeutics, and the National Cancer Institute (NCI), and has consulted for MJH Life Sciences, Arivan Research, Janssen Pharmaceuticals, ADC Therapeutics, Gilead Sciences, GlaxoSmithKline, Caribou Biosciences, Roche, and Autolous Therapeutics. C.L.C. has received research funding from BMS, Takeda Pharmaceuticals, and Janssen Pharmaceuticals, and has consulted for BMS, Janssen Pharmaceuticals, Genentech, Karyopharm Therapeutics, Pfizer, and Kite Pharma. L.S. holds advisory board roles with Novartis, Johnson and Johnson, and BMS. A.R. has received research support from Novartis, Pfizer, and AstraZeneca. M.H.K. and A.Ki. have no conflicts of interest to declare.
